News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
636,106 Results
Type
Article (20275)
Company Profile (201)
Press Release (615626)
Multimedia
Podcasts (55)
Webinars (13)
Section
Business (211849)
Career Advice (702)
Deals (31946)
Drug Delivery (49)
Drug Development (64459)
Employer Resources (57)
FDA (13438)
Job Trends (11714)
News (300414)
Policy (23183)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (1520)
Accelerated approval (29)
ADA (26)
Adcomms (1)
Allergies (156)
Alliances (47236)
ALS (144)
Alzheimer's disease (1283)
Antibody-drug conjugate (ADC) (400)
Approvals (14108)
Artificial intelligence (686)
ASCO (203)
Autoimmune disease (266)
Automation (61)
Bankruptcy (298)
Best Places to Work (9356)
BIO (51)
BIOSECURE Act (7)
Biosimilars (133)
Biotechnology (138)
Bladder cancer (163)
Brain cancer (50)
Breast cancer (621)
Cancer (4827)
Cardiovascular disease (317)
Career advice (612)
Career pathing (12)
CAR-T (306)
CDC (12)
Celiac Disease (1)
Cell therapy (805)
Cervical cancer (47)
Clinical research (57145)
Collaboration (2007)
Company closure (1)
Compensation (1437)
Complete response letters (39)
COVID-19 (1504)
CRISPR (114)
C-suite (1056)
Cystic fibrosis (112)
Data (7035)
Decentralized trials (2)
Denatured (28)
Depression (121)
Dermatology (73)
Diabetes (448)
Diagnostics (6508)
Digital health (64)
Diversity (7)
Diversity, equity & inclusion (12)
Drug discovery (298)
Drug pricing (25)
Drug shortages (7)
Duchenne muscular dystrophy (195)
Earnings (84097)
Editorial (11)
Employer branding (9)
Employer resources (53)
Events (108515)
Executive appointments (986)
FDA (16889)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (17)
Frontotemporal dementia (29)
Funding (1530)
Gene editing (237)
Generative AI (50)
Gene therapy (571)
GLP-1 (497)
Government (1831)
Grass and pollen (4)
Guidances (351)
Healthcare (14503)
Hematology (123)
HIV (66)
Huntington's disease (28)
IgA nephropathy (74)
Immunology and inflammation (135)
Immuno-oncology (70)
Indications (186)
Infectious disease (1780)
Inflammatory bowel disease (160)
Inflation Reduction Act (6)
Influenza (125)
Intellectual property (304)
Interviews (85)
IPO (14987)
IRA (10)
Job creations (2755)
Job search strategy (549)
JPM (22)
Kidney cancer (17)
Labor market (27)
Layoffs (178)
Leadership (8)
Legal (6043)
Liver cancer (71)
Longevity (28)
Lung cancer (591)
Lymphoma (337)
Machine learning (56)
Management (20)
Manufacturing (933)
Marketing (6)
MASH (138)
Medical device (13689)
Medtech (13887)
Mergers & acquisitions (18223)
Metabolic disorders (920)
mRNA (191)
Multiple sclerosis (142)
NASH (7)
Neurodegenerative disease (325)
Neuropsychiatric disorders (52)
Neuroscience (2434)
NextGen: Class of 2026 (5064)
Non-profit (2043)
Now hiring (17)
Obesity (301)
Opinion (118)
Ovarian cancer (189)
Pain (211)
Pancreatic cancer (272)
Parkinson's disease (293)
Partnered (24)
Patents (579)
Patient recruitment (664)
Peanut (61)
People (53165)
Pharmaceutical (40)
Pharmacy benefit managers (12)
Phase 1 (18984)
Phase 2 (25513)
Phase 3 (17217)
Pipeline (8641)
Policy (77)
Postmarket research (1724)
Preclinical (8191)
Press Release (69)
Prostate cancer (264)
Psychedelics (8)
Radiopharmaceuticals (310)
Rare diseases (747)
Real estate (4887)
Recruiting (25)
Regulatory (19426)
Reports (22)
Research institute (1576)
Resumes & cover letters (105)
Rett syndrome (44)
RNA editing (18)
RSV (64)
Schizophrenia (115)
Series A (270)
Series B (193)
Service/supplier (5)
Sickle cell disease (75)
Special edition (1)
Spinal muscular atrophy (106)
Sponsored (25)
Startups (3316)
State (2)
Stomach cancer (4)
Supply chain (77)
Tariffs (11)
The Weekly (25)
Vaccines (683)
Venture capital (65)
Weight loss (110)
Women's health (102)
Worklife (4)
Date
Today (85)
Last 7 days (377)
Last 30 days (1569)
Last 365 days (25273)
2026 (14286)
2025 (25269)
2024 (30189)
2023 (34869)
2022 (45321)
2021 (48752)
2020 (45690)
2019 (36391)
2018 (27339)
2017 (27295)
2016 (26323)
2015 (32821)
2014 (27833)
2013 (23828)
2012 (25751)
2011 (26086)
2010 (24937)
Location
Africa (450)
Alabama (83)
Alaska (6)
Arizona (345)
Arkansas (15)
Asia (33614)
Australia (5230)
California (13120)
Canada (3620)
China (1056)
Colorado (578)
Connecticut (508)
Delaware (284)
Europe (64317)
Florida (1971)
Georgia (426)
Hawaii (3)
Idaho (60)
Illinois (999)
India (75)
Indiana (432)
Iowa (19)
Japan (554)
Kansas (123)
Kentucky (45)
Louisiana (39)
Maine (38)
Maryland (1457)
Massachusetts (9224)
Michigan (389)
Minnesota (724)
Mississippi (6)
Missouri (140)
Montana (31)
Nebraska (19)
Nevada (127)
New Hampshire (89)
New Jersey (3085)
New Mexico (25)
New York (3348)
North Carolina (1604)
North Dakota (10)
Northern California (6481)
Ohio (369)
Oklahoma (22)
Oregon (26)
Pennsylvania (2539)
Puerto Rico (26)
Rhode Island (48)
South America (726)
South Carolina (89)
South Dakota (1)
Southern California (5381)
Tennessee (187)
Texas (2142)
United States (45068)
Utah (404)
Vermont (2)
Virginia (226)
Washington D.C. (52)
Washington State (1075)
West Virginia (3)
Wisconsin (137)
Wyoming (1)
636,106 Results for "visioncare ophthalmic technologies inc visioncare".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
June 4, 2026
·
2 min read
Press Releases
Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy
April 15, 2026
·
1 min read
Press Releases
Health Canada Approves Cysklar® (Cysteamine Ophthalmic Solution) 0.44% for Treatment of Corneal Crystals in People with Cystinosis
April 15, 2026
·
1 min read
Press Releases
Apotex Expands Canadian Ophthalmology Portfolio with Health Canada’s Approval of CLOBIVIS™ (Clobetasol Propionate Ophthalmic Suspension, 0.05%)
March 25, 2026
·
1 min read
Press Releases
ZEISS announces NMPA approval in China for powerful ophthalmic microscopes enhancing surgical visualization
February 3, 2026
·
5 min read
Business
VisionCare, Inc. Names Thomas Ruggia as New Chief Executive Officer
VisionCare, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration, announced that Thomas Ruggia has been appointed as the company’s new Chief Executive Officer, effective July 6, 2020.
July 6, 2020
·
4 min read
Press Releases
ZEISS expands ophthalmic workflow portfolio in Canada with enhanced diagnostic, visualization and therapeutic solutions for precision eye care
March 24, 2026
·
8 min read
Biotech Bay
VisionCare, Inc. Announces CE Mark Approval of the Tsert-SI™ Delivery System for the CentraSight Treatment Program
VisionCare, Inc. (“VisionCare”), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced that receipt of a Conformité Européene (CE) Mark for the Tsert-SI™ delivery system for the CentraSight treatment program
May 11, 2020
·
3 min read
Press Releases
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
February 25, 2026
·
8 min read
Press Releases
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
February 25, 2026
·
6 min read
Previous
2 of 63,611
Next
